The Angelman Syndrome Foundation, www.angelman.org, announced the formation of the Angelman Treatment and Research Institute (ATRI), which will direct the organization's rapidly increasing research funding. The ATRI will also serve as a hub for more than 30 organizations, researchers and scientists worldwide to share discoveries and treatments for this neuro-genetic disorder. The announcement of the ATRI was made during the Angelman Syndrome Foundation's biennial conference in Orlando, Fla.
Orlando, FL (PRWEB) August 6, 2009 -- The Angelman Syndrome Foundation, www.angelman.org, announced the formation of the Angelman Treatment and Research Institute (ATRI), which will direct the organization's rapidly increasing research funding.
News Facts Related to Angelman Syndrome and the ATRI:
- Angelman Syndrome (AS) occurs once in every 15,000 live births and exhibits symptoms such as: developmental delay; lack of speech; seizures; inappropriate laughter; and walking and balance disorders.
- ATRI will realize the Angelman Syndrome Foundation's "scientific roadmap," which will help direct its aggressive funding of AS research.
- Short term focus of the roadmap is to fund research that finds treatments that may cure symptoms of AS while continuing ongoing research and clinical trials involving UBE3A, the abnormal gene in AS patients.
- Research funding will also focus on new therapies for symptoms, pharmaceuticals, biological agents, adaptive devices, surgical and diagnostic procedures.
- An emphasis on adult AS patients will extend the scope of clinical trials to include a wide age group and investigate and advance life and self-help skills, vocational training, and
Copyright©2009 Vocus, Inc.
All rights reserved